Analyst Target Insights: A Closer Look at the First Trust NYSE Arca Biotechnology ETF
Recent analysis of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) reveals significant potential for growth. The study, performed by ETF Channel, compares the trading prices of holdings against average analyst targets, providing insight into future expectations.
Current Price vs. Analyst Expectations
The implied analyst target price for FBT stands at $213.35 per unit, a compelling figure when juxtaposed with its recent trading price of $169.81. This suggests analysts foresee a 25.64% increase for the ETF based on its underlying assets.
Key Holdings with Notable Upside
Among FBT’s holdings, three stocks stand out for their potential upside. Genmab A/S (Symbol: GMAB) currently trades at $20.17/share. Analysts anticipate an 81.89% increase, setting an average target of $36.69/share. Catalyst Pharmaceuticals Inc (Symbol: CPRX) is priced at $21.38, with a forecasted upside of 50.84% to an average target of $32.25/share. Corcept Therapeutics Inc (Symbol: CORT) also shows promise, trading at $55.40 and with a target price of $74.90, indicating a 35.20% potential increase.
Below is a twelve-month price history chart comparing the stock performances of GMAB, CPRX, and CORT:
Overview of Analyst Target Prices
Collectively, GMAB, CPRX, and CORT account for 10.54% of the FBT ETF. The following table summarizes the current analyst target prices:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| First Trust NYSE Arca Biotechnology Index Fund ETF | FBT | $169.81 | $213.35 | 25.64% |
| Genmab A/S | GMAB | $20.17 | $36.69 | 81.89% |
| Catalyst Pharmaceuticals Inc | CPRX | $21.38 | $32.25 | 50.84% |
| Corcept Therapeutics Inc | CORT | $55.40 | $74.90 | 35.20% |
Evaluating Analyst Predictions
Investors may wonder whether analysts’ targets are realistic or overly optimistic. It’s crucial to consider whether these projections are based on recent company performance and industry trends or if they reflect outdated expectations. High price targets can often indicate a positive outlook but may also lead to downgrades if market realities shift.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• MVT Average Annual Return
• Institutional Holders of AUXO
• PPHI Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
